NEW YORK (GenomeWeb) – Dako, an Agilent Technologies company, today announced it has signed an additional collaboration with Amgen to develop a companion diagnostic for an unspecified Amgen cancer drug candidate.

In an email to GenomeWeb, Agilent declined to provide additional details about the agreement.

The deal builds on agreements from 2012 between the two companies, under which Dako was developing several companion diagnostics for drugs from Amgen.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.